While one BCL-2 selective inhibitor (venetoclax) is approved, BCL-2, BCL-XL dual inhibitors such as ABT263 are limited due to on-target inhibition of BCL-XL in platelets that causes thrombocytopenia. This evidence concerns the gene BCL2 and Thrombocytopenia.